March 25, 2024 — Quantum Pathology, LLC, an independent pathology service provider in the United States, today announced the adoption of the AISight[i] Image Management System, a leading end-to-end workflow and image management solution by PathAI. This strategic decision marks a significant step forward in Quantum Pathology's transition to digital pathology, leveraging the advanced capabilities of AISight to revolutionize its operations.
In a rapidly evolving landscape where competition for pathologists and pathology services is intensifying, the integration of digital pathology and artificial intelligence emerges as a crucial differentiator for players in the independent pathology market. After evaluating several image management systems, Quantum Pathology identified the AISight Image Management System as the most compelling solution to streamline its workflow, enhance case prioritization, and facilitate TC/PC use cases. By embracing AISight, Quantum Pathology aims not only to expedite turnaround times for referring physicians but also to harness AI overlays for delivering next-generation insights on patient pathology.
"As the demand for pathology services grows, embracing digital pathology and AI-driven solutions becomes imperative for staying ahead. AISight emerged as the frontrunner among image management systems, offering the versatility and robustness needed to manage our caseload effectively as well as the full menu of algorithms we require to drive efficiencies in our workflow both in-house and amongst our professional clients,” said Dr. May Azar, Chief Medical Officer and Medical Director of Quantum Pathology.
AISight, a cloud-native intelligent enterprise workflow solution, stands as a cornerstone in the digital pathology ecosystem, trusted by hundreds of pathologists worldwide. Serving as a centralized platform for case management, workload balancing, and image management, AISight integrates best-in-class artificial intelligence tools from PathAI and third-party partners. This comprehensive approach enables Quantum Pathology to address a wide spectrum of histopathology use cases with efficiency and precision.
"The adoption of digital pathology represents a pivotal moment in healthcare, and we are witnessing a surge in laboratories embracing innovative image management systems. AISight stands out as a versatile solution that not only delivers high-quality images promptly but also empowers pathologists with a suite of AI algorithms for unparalleled workflow efficiency,” said Eric Walk, MD, FCAP, Chief Medical Officer of PathAI. “We are thrilled to partner with Quantum Pathology and support their journey towards digital transformation."
For more information: https://www.quantumpathology.com/
[i] AISight is For Research Use Only. Not for use in diagnostic procedures.
February 26, 2026 
